Advertisement
Screener

VERICEL CORPORATION (VCEL) Current Ratio

VERICEL CORPORATION (VCEL) Current Ratio

  • Current ratio · latest quarter: Value 5.04×; Formula and calculation Current assets / current liabilities..

Current ratio

Overview →

Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.

MetricValueFormula and calculation
Current ratio · latest quarter5.04×Current assets / current liabilities.

$264.73M ÷ $52.53M ≈ 5.04×

Calculation inputs

InputAmount with unitRaw financial data
Current assets264.73M USDAssets, Current
Current obligations52.53M USDLiabilities, Current
Cash and equivalents125.36M USDCash and Cash Equivalents, at Carrying Value
Short-term securities(m)
Customer receivables75.71M USDAccounts Receivable, after Allowance for Credit Loss, Current
Inventory18.38M USDInventory, Net
Payables20.61M USDAccounts Payable, Current
Borrowing debt due within one year(m)Long-term Debt, Current Maturities

Calculated history

Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.

Period endingCurrent assets (USD)Current obligations (USD)Cash and equivalents (USD)Short-term securities (USD)Customer receivables (USD)Inventory (USD)Payables (USD)Borrowing debt due within one year (USD)Current ratio
2026-06-30$264.73M$52.53M$125.36M(m)$75.71M$18.38M$20.61M(m)5.04×
2026-03-31$244.06M$47.16M$109.30M(m)$72.38M$18.35M$19.01M(m)5.18×
2025-12-31$247.44M$49.15M$100.09M(m)$84.63M$17.56M$15.83M(m)5.03×
2025-09-30$221.97M$45.58M$100.40M(m)$60.43M$18.16M$15.34M(m)4.87×
2025-06-30$204.58M$41.13M$80.53M(m)$64.29M$16.83M$12.86M(m)4.97×
2025-03-31$197.64M$39.45M$73.49M(m)$52.90M$17.11M$16.75M(m)5.01×
2024-12-31$212.78M$50.29M$74.52M(m)$61.38M$17.37M$23.85M(m)4.23×
2024-09-30$190.52M$41.35M$53.68M(m)$48.48M$15.76M$20.88M(m)4.61×
2024-06-30$197.39M$43.86M$50.29M(m)$48.00M$14.89M$25.22M(m)4.50×
2024-03-31$189.72M$36.47M$62.94M(m)$49.93M$13.56M$19.43M(m)5.20×
2023-12-31$205.63M$45.75M$69.09M(m)$58.36M$13.09M$22.35M(m)4.49×
2023-09-30$186.21M$35.95M$60.47M(m)$39.73M$12.62M$15.05M(m)5.18×
2023-06-30$182.87M$35.61M$43.02M(m)$38.32M$13.88M$14.40M(m)5.14×
2023-03-31$177.54M$28.75M$61.83M(m)$38.36M$15.37M$11.13M(m)6.17×
2022-12-31$186.87M$37.46M$51.07M(m)$46.54M$15.99M$16.93M(m)4.99×
2022-09-30$166.38M$27.00M$65.22M(m)$34.30M$16.73M$8.11M(m)6.16×
2022-06-30$155.09M$25.01M$56.05M(m)$33.66M$15.93M$9.68M(m)6.20×
2022-03-31$151.88M$21.73M$55.66M(m)$31.86M$14.38M$7.75M(m)6.99×
2021-12-31$158.46M$26.05M$68.33M(m)$37.44M$13.38M$9.02M(m)6.08×
2021-09-30$144.95M$18.83M$54.55M(m)$28.91M$13.06M$5.58M(m)7.70×
2021-06-30$138.52M$23.86M$51.76M(m)$31.73M$12.96M$8.13M(m)5.80×
2021-03-31$127.21M$23.23M$58.15M(m)$29.12M$10.32M$8.83M(m)5.48×
2020-12-31$123.56M$22.48M$33.62M(m)$34.50M$9.36M$6.75M(m)5.50×
2020-09-30$125.38M$21.31M$43.51M(m)$26.17M$10.08M$6.47M(m)5.88×
2020-06-30$115.76M$18.12M$55.70M(m)$23.66M$8.42M$4.54M(m)6.39×
2020-03-31$116.54M$18.13M$45.62M(m)$24.17M$7.28M$6.40M(m)6.43×
2019-12-31$111.66M$19.80M$26.89M(m)$32.17M$6.82M$6.34M(m)5.64×
2019-09-30$104.72M$15.11M$36.91M(m)$19.96M$6.82M$5.28M(m)6.93×
2019-06-30$94.05M$12.54M$13.96M(m)$21.08M$4.79M$5.25M(m)7.50×
2019-03-31$109.60M$12.94M$35.08M(m)$18.77M$4.06M$6.20M(m)8.47×
2018-12-31$112.78M$14.79M$18.29M(m)$23.45M$3.56M$7.11M(m)7.62×
2018-09-30$119.26M$14.99M$53.29M(m)$15.53M$3.64M$4.58M(m)7.95×
2018-06-30$117.52M$15.22M$94.97M(m)$17.50M$3.73M$5.01M(m)7.72×
2018-03-31$48.20M$13.88M(m)(m)$13.16M$3.90M$5.77M(m)3.47×
2017-12-31$50.51M$13.09M(m)(m)$18.27M$3.79M$5.55M(m)3.86×
2017-09-30$36.31M$14.53M(m)(m)$15.43M$4.05M$5.97M(m)2.50×
2017-06-30$33.04M$12.94M(m)(m)$14.73M$3.15M$6.27M(m)2.55×
2017-03-31$36.95M$14.75M(m)(m)$12.13M$3.96M$6.33M(m)2.50×
2016-12-31$44.72M$12.85M(m)(m)$17.09M$3.49M$6.54M(m)3.48×
2016-09-30$21.10M$15.36M(m)(m)$7.87M$3.61M$5.47M(m)1.37×
2016-06-30$22.30M$11.46M(m)(m)$9.03M$2.39M$5.30M(m)1.95×
2016-03-31$25.82M$13.77M(m)(m)$9.67M$1.94M$6.29M(m)1.88×
2015-12-31$27.34M$12.11M(m)(m)$10.92M$1.38M$7.59M(m)2.26×
2015-09-30$28.52M$9.26M(m)(m)$7.64M$1.64M$5.00M(m)3.08×
2015-06-30$33.55M$10.82M(m)(m)$8.98M$2.08M$6.12M(m)3.10×
2015-03-31$37.92M$12.62M(m)(m)$9.17M$2.00M$6.73M(m)3.00×
2014-12-31$41.49M$11.83M(m)(m)$8.19M$1.92M$5.82M(m)3.51×
2014-09-30$44.72M$12.48M(m)(m)$3.96M$1.71M$2.50M$38.00K3.58×
2014-06-30$14.11M$17.05M(m)(m)$4.32M$1.92M$2.91M(m)0.83×
2014-03-31$9.24M$6.11M(m)(m)(m)(m)(m)$2.00K1.51×
2013-12-31$8.48M$5.32M(m)(m)$8.00K(m)$2.68M(m)1.59×
2013-09-30$11.36M$7.25M$10.82M(m)(m)(m)(m)$10.00K1.57×
2013-06-30$4.73M$3.84M$4.49M(m)(m)(m)(m)$19.00K1.23×
2013-03-31$9.53M$4.28M$9.23M(m)(m)(m)(m)$27.00K2.23×
2012-12-31$13.99M$5.66M$13.64M(m)(m)(m)$2.84M$34.00K2.47×
2012-09-30$21.46M$6.98M$21.09M(m)(m)(m)(m)$40.00K3.07×
2012-06-30$29.13M$11.99M$28.67M(m)(m)(m)(m)$40.00K2.43×
2012-03-31$37.20M$22.35M$36.73M(m)(m)(m)(m)$40.00K1.66×
2011-12-31$6.17M$20.67M$5.53M(m)(m)(m)$2.24M$40.00K0.30×
2011-09-30$12.58M$25.18M$11.95M(m)(m)(m)(m)$51.00K0.50×
2011-06-30$19.05M$30.42M$18.52M(m)(m)(m)(m)$103.00K0.63×
2010-12-31$31.70M$29.86M$31.25M(m)(m)(m)(m)$214.00K1.06×

(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.

Similar stocks

Stock NameCountryMarket CapPE Ratio
RECURSION PHARMACEUTICALS, INC. (RXRX)United States$2.080B-3.78
Kodiak Sciences Inc. (KOD)United States$2.090B-10.12
ADMA BIOLOGICS, INC. (ADMA)United States$2.131B11.16
BIOCRYST PHARMACEUTICALS INC (BCRX)United States$2.175B-6.63
Vir Biotechnology, Inc. (VIR)United States$1.814B-6.85
NOVAVAX INC (NVAX)United States$1.748B-6.26
Hemab Therapeutics Holdings, Inc. (COAG)United States$1.672B
Greenland Mines Ltd (GRML)United States$2.362B
Immunocore Holdings plc (IMCR)$1.613B-90.43
Taysha Gene Therapies, Inc. (TSHA)United States$1.564B-14.80